Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura

Harumi Y. Mukai, Hiroshi Kojima, Kazuo Todokoro, Tomoyuki Tahara, Takashi Kato, Yuichi Hasegawa, Toshitaka Kobayashi, Haruhiko Ninomiya, Toshiro Nagasawa, Tsukasa Abe

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We assayed serum thrombopoietin (TPO) levels in amegakaryocytic thrombocytopenia (AMT) and immune thrombocytopenic purpura (ITP) patients by using a newly established enzyme-linked immunosorbent assay (ELISA). TPO levels in AMT patients were quite high (mean ± SD = 13.7 ± 11.2 fmoles/ml, n = 4), whereas those in ITP patients were only slightly higher (1.25 ± 0.39, n = 12) than those of the healthy donors (0.55 ± 0.2, n = 20). Furthermore, in ITP patients no correlation was observed between platelet counts and serum TPO levels (correlation coefficient = 0.14). We further assayed serum TPO levels sequentially during steroid treatment in patients with AMT and ITP. In one AMT patient serum TPO levels started to decrease in accordance with the increase of megakaryocyte counts, which preceded the increase in platelet counts. However, in ITP patients serum TPO levels did not change significantly throughout the course of the treatment despite the recovery of platelet counts. Based on these findings, we conclude that serum TPO levels may be regulated at least in part by megakaryocyte counts.

Original languageEnglish
Pages (from-to)675-678
Number of pages4
JournalThrombosis and Haemostasis
Volume76
Issue number5
Publication statusPublished - 1996 Nov
Externally publishedYes

Fingerprint

Thrombopoietin
Idiopathic Thrombocytopenic Purpura
Thrombocytopenia
Serum
Platelet Count
Megakaryocytes
Enzyme-Linked Immunosorbent Assay
Steroids
Tissue Donors
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. / Mukai, Harumi Y.; Kojima, Hiroshi; Todokoro, Kazuo; Tahara, Tomoyuki; Kato, Takashi; Hasegawa, Yuichi; Kobayashi, Toshitaka; Ninomiya, Haruhiko; Nagasawa, Toshiro; Abe, Tsukasa.

In: Thrombosis and Haemostasis, Vol. 76, No. 5, 11.1996, p. 675-678.

Research output: Contribution to journalArticle

Mukai, HY, Kojima, H, Todokoro, K, Tahara, T, Kato, T, Hasegawa, Y, Kobayashi, T, Ninomiya, H, Nagasawa, T & Abe, T 1996, 'Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura', Thrombosis and Haemostasis, vol. 76, no. 5, pp. 675-678.
Mukai, Harumi Y. ; Kojima, Hiroshi ; Todokoro, Kazuo ; Tahara, Tomoyuki ; Kato, Takashi ; Hasegawa, Yuichi ; Kobayashi, Toshitaka ; Ninomiya, Haruhiko ; Nagasawa, Toshiro ; Abe, Tsukasa. / Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. In: Thrombosis and Haemostasis. 1996 ; Vol. 76, No. 5. pp. 675-678.
@article{93763da158cc401d823740b46bd36f85,
title = "Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura",
abstract = "We assayed serum thrombopoietin (TPO) levels in amegakaryocytic thrombocytopenia (AMT) and immune thrombocytopenic purpura (ITP) patients by using a newly established enzyme-linked immunosorbent assay (ELISA). TPO levels in AMT patients were quite high (mean ± SD = 13.7 ± 11.2 fmoles/ml, n = 4), whereas those in ITP patients were only slightly higher (1.25 ± 0.39, n = 12) than those of the healthy donors (0.55 ± 0.2, n = 20). Furthermore, in ITP patients no correlation was observed between platelet counts and serum TPO levels (correlation coefficient = 0.14). We further assayed serum TPO levels sequentially during steroid treatment in patients with AMT and ITP. In one AMT patient serum TPO levels started to decrease in accordance with the increase of megakaryocyte counts, which preceded the increase in platelet counts. However, in ITP patients serum TPO levels did not change significantly throughout the course of the treatment despite the recovery of platelet counts. Based on these findings, we conclude that serum TPO levels may be regulated at least in part by megakaryocyte counts.",
author = "Mukai, {Harumi Y.} and Hiroshi Kojima and Kazuo Todokoro and Tomoyuki Tahara and Takashi Kato and Yuichi Hasegawa and Toshitaka Kobayashi and Haruhiko Ninomiya and Toshiro Nagasawa and Tsukasa Abe",
year = "1996",
month = "11",
language = "English",
volume = "76",
pages = "675--678",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "5",

}

TY - JOUR

T1 - Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura

AU - Mukai, Harumi Y.

AU - Kojima, Hiroshi

AU - Todokoro, Kazuo

AU - Tahara, Tomoyuki

AU - Kato, Takashi

AU - Hasegawa, Yuichi

AU - Kobayashi, Toshitaka

AU - Ninomiya, Haruhiko

AU - Nagasawa, Toshiro

AU - Abe, Tsukasa

PY - 1996/11

Y1 - 1996/11

N2 - We assayed serum thrombopoietin (TPO) levels in amegakaryocytic thrombocytopenia (AMT) and immune thrombocytopenic purpura (ITP) patients by using a newly established enzyme-linked immunosorbent assay (ELISA). TPO levels in AMT patients were quite high (mean ± SD = 13.7 ± 11.2 fmoles/ml, n = 4), whereas those in ITP patients were only slightly higher (1.25 ± 0.39, n = 12) than those of the healthy donors (0.55 ± 0.2, n = 20). Furthermore, in ITP patients no correlation was observed between platelet counts and serum TPO levels (correlation coefficient = 0.14). We further assayed serum TPO levels sequentially during steroid treatment in patients with AMT and ITP. In one AMT patient serum TPO levels started to decrease in accordance with the increase of megakaryocyte counts, which preceded the increase in platelet counts. However, in ITP patients serum TPO levels did not change significantly throughout the course of the treatment despite the recovery of platelet counts. Based on these findings, we conclude that serum TPO levels may be regulated at least in part by megakaryocyte counts.

AB - We assayed serum thrombopoietin (TPO) levels in amegakaryocytic thrombocytopenia (AMT) and immune thrombocytopenic purpura (ITP) patients by using a newly established enzyme-linked immunosorbent assay (ELISA). TPO levels in AMT patients were quite high (mean ± SD = 13.7 ± 11.2 fmoles/ml, n = 4), whereas those in ITP patients were only slightly higher (1.25 ± 0.39, n = 12) than those of the healthy donors (0.55 ± 0.2, n = 20). Furthermore, in ITP patients no correlation was observed between platelet counts and serum TPO levels (correlation coefficient = 0.14). We further assayed serum TPO levels sequentially during steroid treatment in patients with AMT and ITP. In one AMT patient serum TPO levels started to decrease in accordance with the increase of megakaryocyte counts, which preceded the increase in platelet counts. However, in ITP patients serum TPO levels did not change significantly throughout the course of the treatment despite the recovery of platelet counts. Based on these findings, we conclude that serum TPO levels may be regulated at least in part by megakaryocyte counts.

UR - http://www.scopus.com/inward/record.url?scp=10544241190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10544241190&partnerID=8YFLogxK

M3 - Article

VL - 76

SP - 675

EP - 678

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 5

ER -